Medical News

RSS

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

AVEO Pharmaceuticals, Inc. today announced that preclinical data on tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company's monoclonal antibody pipeline will be presented during poster sessions at the American Association for Cancer Research 102nd Annual Meeting 2011 being held April 2-6, 2011 in Orlando, Fla.

28 Mar 2011

Leicester professor receives Outstanding Alumni Achievement Award for Cardiovascular research

The winner of the University of Leicester inaugural Outstanding Alumni Achievement Award was revealed at the 2011 Alumni Black Tie Dinner on Thursday 17 February at the Mandarin Hotel in London.

28 Mar 2011

GE launches new specialty musculoskeletal MR scanner

GE today announced the launch of the Optima MR430s, a new specialty scanner with breakthrough technology that delivers precise imaging with exceptional comfort and the 1.5T image quality radiologists require.

28 Mar 2011

Drugs can prevent risk of breast cancer in women, experts say

Drugs could be used to prevent breast cancer in women at high risk of the disease in the same way that statins are used for heart disease if trials looking at ways of predicting risk are successful, according to an international panel of cancer experts.

28 Mar 2011

Toshiba introduces new Infinix-i cardiovascular X-ray systems

Accurately navigating and interpreting cardiovascular anatomy for precise device deployment is a challenge to physicians during complex interventional procedures. Providing physicians with greater confidence during these difficult procedures, Toshiba America Medical Systems, Inc. is introducing upgrades to its Infinix-i product line.

28 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

A.P. Pharma fourth quarter revenue decreases to $1.6 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2010 and provided a corporate update.

28 Mar 2011

RDY introduces Levocetirizine tablets in the U.S. market

Dr. Reddy's Laboratories has launched Levocetirizine tablets, a bioequivalent generic version of Xyzal tablets in the US market. The United States Food & Drug Administration approved Dr. Reddy's ANDA for Levocetirizine tablets on February 24, 2011.

28 Mar 2011

DAW prescriptions can increase annual health system costs to $7.7 billion

Approximately five percent of prescriptions submitted by CVS Caremark Pharmacy Benefit Management members in a 30-day period during 2009 included a "dispense as written" designation.

28 Mar 2011

MRF: FDA's decision on Yervoy offers new treatment options for patients with melanoma

Thirteen years of waiting is now over for melanoma patients. That's how long it's been since the last therapy became available to treat the most lethal form of skin cancer – melanoma. The FDA today announced approval of Yervoy, an immunotherapy treatment for advanced melanoma.

28 Mar 2011

Research: Written action plan with prescriptions can improve asthma control in children

It sounds unbelievably simple but it's true - a written action plan for asthma treatment, attached to the drug prescription, improves asthma control in children. "Acute care visits for asthma often signal a management failure," said Dr. Francine Ducharme, of the University of Montreal's Department of Pediatrics and the Sainte-Justine University Hospital Centre.

28 Mar 2011

Essex scientists receive £205,000 grant for breast cancer research

Scientists from the University of Essex have received a £205,000 grant from Cancer Research UK to investigate the early reversible changes in the genes associated with breast cancer development.

28 Mar 2011

CBAI partners with BlueCross and offers cord blood banking services to their members

Cord Blood America, Inc., announced today it has entered into an agreement with BlueCross BlueShield of Tennessee and is now offering the storage of umbilical cord blood at a discount rate as consistent with its other BCBS licensee contracts.

28 Mar 2011

Conference to address new treatments, technologies from biomedical research

New treatments and technologies emerging from the field of biomedical research have prompted demands for updated ethical guidelines.

28 Mar 2011

U.S. FDA approves Yervoy to treat patients with late-stage melanoma

The U.S. Food and Drug Administration today approved Yervoy to treat patients with late-stage melanoma, the most dangerous type of skin cancer.

28 Mar 2011

ALCMI launches new CASTLE study to treat lung cancer

The Addario Lung Cancer Medical Institute today announced the enrollment of the initial subjects into its inaugural clinical trial known as CASTLE, targeting 250 subjects over two years among academic and community medical centers in the United States.

28 Mar 2011

University of Aberdeen, TPP enter agreement to develop novel future medicines

TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.

28 Mar 2011

Artimplant's Artelon CMC Soft receives European CE-mark approval

In collaboration with Small Bone Innovations, Artimplant has developed a new product in the Artelon Spacer range with a similar user-friendly textile design to Artelon Tissue Reinforcement.

28 Mar 2011

Molecular pharmacologist receives AACR Award for cancer research

Susan Band Horwitz, Ph.D., will receive the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel, which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas.

28 Mar 2011

Precise Biometrics announces SEK 54 million financing through rights offering

The Board of Directors of Precise Biometrics has resolved, subject to approval of the AGM on April 27, to undertake an issue with preferential rights for Precise Biometrics' shareholders that will raise a maximum of SEK 54 million before deduction of issue related costs.

28 Mar 2011